Cure Parkinson’s International Linked Clinical Trials (iLCT) Pipeline Research Acceleration Programme is welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s.
Each year, a committee of over 20 world-leading Parkinson’s experts meet to evaluate, rank, and prioritise potentially disease-modifying drugs for Parkinson’s as part of their iLCT programme. The goal of this initiative is to accelerate the movement of drugs through the development pipeline by prioritising the most promising candidates for clinical testing.
Sometimes, drugs reviewed by the iLCT committee show potential but lack a specific piece of preclinical evidence. To speed-up this process, Cure Parkinson’s launched the iLCT Pipeline Research Acceleration Programme. This programme commissions researchers to conduct a specific project which, in this case, is to investigate secukinumab in an alpha-synuclein model of Parkinson’s.
| Sign up to the ACNR email newsletter here |
Secukinumab has been evaluated twice by the iLCT committee, first in 2018 and again in 2025 due to new evidence being published. The committee have suggested that additional data is needed before secukinumab can progress into clinical trial for Parkinson’s, specifically how it performs in alpha-synuclein models of the condition.
More details including the project outline and application process can be found on the International Linked Clinical Trials Programme webpage. Applications will be accepted until 11.59pm, Tuesday 7th April, 2026.
Sources
| Sign up for our online community for neurology specialists |
